Glycomimetics INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Crescent Biopharma announces strategic partnerships with Kelun-Biotech and Paragon Therapeutics, securing $100 million in upfront payments and advancing its oncology pipeline with CR-001, CR-002, and SKB105 (CR-003) towards Phase 1/2 trials in 2026.